London, UK: 15 August 2006 Cancer drug developer Antisoma plc (LSE:
ASM, US OTC: ATSMY) today provides an update on its commercialisation
strategy for AS1404 and progress in the drug's clinical trials.

AS1404 partnering process progressing
Over the past two months, there has been considerable interest from
potential licensing partners for AS1404. Discussions are advancing
with a number of these. AS1404 addresses very large market
opportunities such as lung and prostate cancers. Maximising revenues
in these indications requires a substantial infrastructure. Antisoma
intends to partner AS1404 with a strong development and marketing
organisation.

Antisoma's CEO, Glyn Edwards, said: "There are few phase III oncology
products available for licensing with strong data from controlled
phase II studies, so it's not surprising that we've seen a high level
of interest in AS1404. We are confident that we can secure a deal
which reflects the advanced stage and blockbuster potential of this
drug."

All AS1404 phase II trials now fully recruited
While preparing for a phase III trial in lung cancer, Antisoma
continues to progress AS1404 through its phase II programme. The
Company announces today that it has completed enrollment into two
more phase II studies:

(1) A controlled trial in hormone-refractory prostate cancer
Seventy-four men have been randomly assigned to receive either AS1404
plus docetaxel or docetaxel alone. This trial is being conducted at
hospitals in the USA and Australia. It has been running alongside
separate trials in lung and ovarian cancers.

(2) An extension of the phase II trial in non-small cell lung cancer
A further 24 patients have received 1800 mg/m2 AS1404 in combination
with carboplatin and paclitaxel in an open-label extension to the
phase II lung cancer trial. Patients have been enrolled in Germany,
Australia and New Zealand. This study is designed to further define
the safety window for the drug.

With these developments, all phase II trials of AS1404 are now fully
recruited. There will be several reports of data from these studies
over the coming months.

Commenting on the prostate cancer trial, Dr Paul Mainwaring, Director
of Medical Oncology at the Mater Hospital in Brisbane, Australia and
an investigator in the study, said: "We're pleased to be
participating in the first study of a vascular disrupting agent in
prostate cancer. Given the promise shown by an AS1404-taxane
combination in lung cancer it will be very interesting to see how
AS1404 combines with a different taxane in prostate cancer."



Enquiries:
Glyn Edwards, Chief Executive Officer
Daniel Elger, Director of Communications          +44 (0)20 8799 8200
Antisoma plc

Mark Court/Lisa Baderoon/Rebecca Skye
Dietrich
Buchanan Communications                           +44 (0)20 7466 5000




Antisoma disclaimer
Certain matters discussed in this statement are forward looking
statements that are subject to a number of risks and uncertainties
that could cause actual results to differ materially from results,
performance or achievements expressed or implied by such statements.
These risks and uncertainties may be associated with product
discovery and development, including statements regarding the
company's clinical development programmes, the expected timing of
clinical trials and regulatory filings. Such statements are based on
management's current expectations, but actual results may differ
materially.

Background on AS1404
AS1404 (DMXAA) is a small-molecule vascular disrupting agent which
targets the blood vessels that nourish tumours. The drug was
discovered by Professors Bruce Baguley and William Denny and their
teams at the Auckland Cancer Society Research Centre, University of
Auckland, New Zealand. It was in-licensed by Antisoma from Cancer
Research Ventures Limited (now Cancer Research Technologies) in
August 2001.

Background on Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that
develops novel products for the treatment of cancer. Antisoma fills
its development pipeline by acquiring promising new product
candidates from internationally recognised academic or cancer
research institutions. Its core activity is the preclinical and
clinical development of these drug candidates. Please visit
www.antisoma.com for further information.

---END OF MESSAGE---

Investegate takes no responsibility for the accuracy of the information within the site.

The announcements are supplied by the denoted source. Queries about the content of an announcement should be directed to the source. Investegate reserves the right to publish a filtered set of announcements. NAV, EMM/EPT, Rule 8 and FRN Variable Rate Fix announcements are filitered from this site.

     © 2012 Financial Express. All rights reserved.